[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraoral-photobiomodulation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraoral-photobiomodulation-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100465033","intraoral-photobiomodulation-therapy-to-prevent-oral-mucositis-in-patients-undergoing-hematopoietic-cell-transplantation-100465033",false,"NCT05335434","Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation","A Single Center Pilot Study of Intraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis in Patients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.\n* Age ≥18 years.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT.\n* Participants who have a history of radiation therapy to the head and neck.\n* Participants who have a history of photosensitivity or underlying disease with known photosensitivity.\n* Participants who are planned to receive palifermin for OM prevention.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device.\n\nThe name of the study device involved in this study is:\n\n\\- THOR LX2.3 with LED Lollipop",[26,27,28,29],"Myeloablative Allogeneic Hematopoietic Cell Transplantation","Intraoral Photobiomodulation Therapy","Oral Mucositis","Mucosal Ulcer",[31,27,28,29],"Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)","RECRUITING","2025-12-08",{"date":35,"type":36},"2025-12-15","ACTUAL",{"date":38,"type":36},"2022-06-10",{"date":40,"type":20},"2026-07-19",{"name":42,"class":43},"Dana-Farber Cancer Institute","OTHER"]